Arcturus Therapeutics Holdings Inc. has announced a significant $50 million investment from Meiji Seika Pharma Co., Ltd. This deal, finalized on November 16, 2026, is part of an expanded collaboration aimed at advancing Arcturus' messenger RNA (mRNA) technology. The investment is notable for being at an 80% premium to the average closing price of Arcturus' common stock over the preceding 30 trading days, underscoring strong market confidence in the company's future.
This partnership, which includes a memorandum of understanding for pandemic preparedness and a license agreement for the application of Arcturus' ARCT-154 technology, is expected to bolster the company's efforts in developing innovative therapeutic solutions. Joseph Payne, the CEO of Arcturus, expressed optimism about the collaboration, highlighting its potential to enhance patient outcomes through advanced mRNA medicines.
Background
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. operates in the pharmaceutical preparations sector (SIC 2834). The company focuses on developing mRNA-based therapeutics for liver and respiratory diseases. Its notable technologies include the LUNAR lipid-mediated delivery system and self-amplifying mRNA (sa-mRNA) platforms. Arcturus is publicly traded on the Nasdaq under the ticker symbol ARCT.
What the Filing Says
The SEC filing details the terms of the Securities Purchase Agreement with Meiji, which includes the sale of 2,466,395 shares of common stock for a total of $50 million. The purchase price of $20.27 per share represents a significant premium, reflecting the potential value attributed to Arcturus' mRNA technology. The agreement also stipulates that if a definitive license agreement is not reached by May 31, 2027, Arcturus must refund 50% of the premium to Meiji.
Additionally, the filing outlines the standstill provisions that prevent Meiji from acquiring more than 9.9% of Arcturus' outstanding shares for 24 months. It also grants Meiji rights to participate in future equity offerings, subject to the same ownership limitation.
Impact
This investment and collaboration may significantly impact various stakeholders, including patients, healthcare providers, and investors in the pharmaceutical sector. The partnership aims to accelerate the development of ARCT-2601, targeting OTC deficiency, and enhance Arcturus' capabilities in mRNA technology, which could lead to new treatment options in the market.
What's Next
The filing does not specify the next steps following this investment, but it indicates that the agreements will be incorporated into Arcturus' upcoming Annual Report on Form 10-K for the year ended December 31, 2026.
Read Next
CION Investment Corp partners with BC Partners for acquisition
Spangler acquires 2,006 shares of Brady Corp stock
Robinson Scott J. acquires shares in Brady Corp as director
Primo Brands Corp to Offer $700 Million in Senior Notes
Air Industries Group to Vote on Tenax Merger November 18
SunPower Inc. announces 1-for-35 reverse stock split







